Drug Profile
Upifitamab rilsodotin - Adimab/Mersana Therapeutics
Alternative Names: UpRi - Mersana Therapeutics; XMT-1536Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Adimab; Mersana Therapeutics
- Developer Mersana Therapeutics
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 24 Oct 2023 Mersana Therapeutics terminates phase III UP-NEXT trial in Fallopian tube cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Recurrent) in US, Australia, Canada, France, Germany, Austria, Sweden, Spain, Israel, South Korea, Norway and Denmark due to sponsor decision (IV) (NCT05329545)
- 24 Oct 2023 Mersana Therapeutics terminates phase III UP-NEXT trial in Ovarian cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Recurrent) in US, Australia, Canada, France, Germany, Austria, Sweden, Spain, Israel, South Korea, Norway and Denmark due to sponsor decision (IV) (NCT05329545)